Literature DB >> 27519269

DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.

Petr Dmitriev1, Yara Bou Saada2, Carla Dib2, Eugénie Ansseau3, Ana Barat2, Aline Hamade4, Philippe Dessen5, Thomas Robert5, Vladimir Lazar5, Ruy A N Louzada6, Corinne Dupuy6, Vlada Zakharova7, Gilles Carnac8, Marc Lipinski2, Yegor S Vassetzky9.   

Abstract

Facioscapulohumeral dystrophy (FSHD) is one of the three most common muscular dystrophies in the Western world, however, its etiology remains only partially understood. Here, we provide evidence of constitutive DNA damage in in vitro cultured myoblasts isolated from FSHD patients and demonstrate oxidative DNA damage implication in the differentiation of these cells into phenotypically-aberrant myotubes. Double homeobox 4 (DUX4), the major actor in FSHD pathology induced DNA damage accumulation when overexpressed in normal human myoblasts, and RNAi-mediated DUX4 inhibition reduced the level of DNA damage in FSHD myoblasts. Addition of tempol, a powerful antioxidant, to the culture medium of proliferating DUX4-transfected myoblasts and FSHD myoblasts reduced the level of DNA damage, suggesting that DNA alterations are mainly due to oxidative stress. Antioxidant treatment during the myogenic differentiation of FSHD myoblasts significantly reduced morphological defects in myotube formation. We propose that the induction of DNA damage is a novel function of the DUX4 protein affecting myogenic differentiation of FSHD myoblasts.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antioxidants; DNA damage; DUX4; Facioscapulohumeral dystrophy; Oxidative stress

Mesh:

Substances:

Year:  2016        PMID: 27519269     DOI: 10.1016/j.freeradbiomed.2016.08.007

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  37 in total

1.  Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity.

Authors:  Emanuela Teveroni; Marsha Pellegrino; Sabrina Sacconi; Patrizia Calandra; Isabella Cascino; Stefano Farioli-Vecchioli; Angela Puma; Matteo Garibaldi; Roberta Morosetti; Giorgio Tasca; Enzo Ricci; Carlo Pietro Trevisan; Giuliana Galluzzi; Alfredo Pontecorvi; Marco Crescenzi; Giancarlo Deidda; Fabiola Moretti
Journal:  J Clin Invest       Date:  2017-03-06       Impact factor: 14.808

Review 2.  Control of DNA integrity in skeletal muscle under physiological and pathological conditions.

Authors:  Yara Bou Saada; Vlada Zakharova; Boris Chernyak; Carla Dib; Gilles Carnac; Svetlana Dokudovskaya; Yegor S Vassetzky
Journal:  Cell Mol Life Sci       Date:  2017-04-25       Impact factor: 9.261

3.  Dynamic transcriptomic analysis reveals suppression of PGC1α/ERRα drives perturbed myogenesis in facioscapulohumeral muscular dystrophy.

Authors:  Christopher R S Banerji; Maryna Panamarova; Johanna Pruller; Nicolas Figeac; Husam Hebaishi; Efthymios Fidanis; Alka Saxena; Julian Contet; Sabrina Sacconi; Simone Severini; Peter S Zammit
Journal:  Hum Mol Genet       Date:  2019-04-15       Impact factor: 6.150

4.  Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.

Authors:  Anita van den Heuvel; Ahmed Mahfouz; Susan L Kloet; Judit Balog; Baziel G M van Engelen; Rabi Tawil; Stephen J Tapscott; Silvère M van der Maarel
Journal:  Hum Mol Genet       Date:  2019-04-01       Impact factor: 6.150

Review 5.  Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.

Authors:  Johanna Hamel; Rabi Tawil
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 6.  Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.

Authors:  Amy E Campbell; Andrea E Belleville; Rebecca Resnick; Sean C Shadle; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

Review 7.  Promising Perspective to Facioscapulohumeral Muscular Dystrophy Treatment: Nutraceuticals and Phytochemicals.

Authors:  Ceren Hangül; Sibel Berker Karaüzüm; Esra Küpeli Akkol; Devrim Demir-Dora; Zafer Çetin; Eyüp İlker Saygılı; Gökhan Evcili; Eduardo Sobarzo-Sánchez
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

8.  Transcriptomic pathway analysis of urokinase receptor silenced breast cancer cells: a microarray study.

Authors:  Pavan B Narayanaswamy; Tapan K Baral; Hermann Haller; Inna Dumler; Kshitish Acharya; Yulia Kiyan
Journal:  Oncotarget       Date:  2017-09-28

Review 9.  Are Antioxidants a Potential Therapy for FSHD? A Review of the Literature.

Authors:  Adam Philip Denny; Alison Kay Heather
Journal:  Oxid Med Cell Longev       Date:  2017-06-12       Impact factor: 6.543

Review 10.  p38 MAPKs - roles in skeletal muscle physiology, disease mechanisms, and as potential therapeutic targets.

Authors:  Christopher M Brennan; Charles P Emerson; Jane Owens; Nicolas Christoforou
Journal:  JCI Insight       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.